
In a regulatory filing first seen by news provider Citybizlist, seven investors have provided the money and the company has directors from Castletop Capital, Watermark Medical, Thomson, Ritchie Capital, Blackstone Group and GMG Capital Partners.
The money will be drawn down in two tranches over the next two years to fund phase three development of Circassia's cat and ragweed allergy therapies.
Alongside Google Ventures and SalesForce in backing HubSpot's $32m D round were venture capital firms Sequoia Capital, General Catalyst Partners, Matrix Partners and Scale Venture Partners.
Novo joined Merck Capital Ventures, the corporate venturing unit of US-based drugs company Merck & Co, in the High Throughput Genomics investment consortium along with venture capital firms Fletcher Spaght Ventures, Solstice Capital and Valley Ventures.
Last year, Digital became one of the top five global games publishers on social network Facebook with more than 12 million monthly active users and has raised $12m in its D round.
In a regulatory filing, CalciMedica said it had raised $9.2m. Two-thirds of this money is released following a clinical milestone for its CM2489 once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis.
Venture capital firm Mohr Davidow Ventures led the round for Coupa alongside peers El Dorado Ventures, Battery Ventures and BlueRun Ventures, which span off from phone maker Nokia in 2005 but retains the Finland-based former parent as an investor.
Alongside Ascension Health Ventures in the D round consortium are venture capital firms Split Rock Partners, Legacy Life Sciences, EDF Ventures, MedVenture Associates, DFJ InCube Ventures, Emergent Medical Partners and Asset Management Partners.
Ascension Health Ventures leads $14m D round for Ocular Therapeutix.
Japan-based manufacturers Fujikura and NTT Electronics (NEL) back Nistica's D round.